Largest pharmaceuticals by total debt
Borrowings at the end of the latest fiscal year: long-term debt including the part due within a year, plus short-term borrowings. Leases are left out unless the company reports them in one figure with its debt.
AbbVie leads the 35 pharmaceuticals ranked by total debt, at SGD 87B, ahead of Pfizer (SGD 83.6B) and Merck & Co (SGD 63.6B). Figures as of 18 Nov 2026, 15:26 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 35
- First
- AbbVieSGD 87B
- Median
- SGD 6.8B
- Combined market value
- SGD 6.58T
- Countries
- 10
- Not ranked
- 26no total debt on file
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | Total debt ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AbbVieABBV · Health Care | SGD 87B | SGD 657.2B | SGD 371.77 | 1.55% down | 26% up | ||
| 2 | PfizerPFE · Health Care | SGD 83.6B | SGD 207.5B | SGD 36.41 | 0.84% down | 14% up | ||
| 3 | Merck & CoMRK · Health Care | SGD 63.6B | SGD 446.1B | SGD 180.95 | 2.14% down | 51% up | ||
| 4 | Johnson & JohnsonJNJ · Health Care | SGD 61.8B | SGD 855.3B | SGD 355.30 | 1.15% down | 38% up | ||
| 5 | Bristol-Myers SquibbBMY · Health Care | SGD 58.2B | SGD 158.4B | SGD 77.50 | 2.05% down | 34% up | ||
| 6 | Eli LillyLLY · Health Care | SGD 54.8B | SGD 1.61T | SGD 1,802.91 | 1.24% down | 35% up | ||
| 7 | Takeda PharmaceuticalTAK · Health Care | SGD 39.4B | SGD 88.2B | SGD 27.61 | 1.06% down | 54% up | ||
| 8 | AstraZenecaAZN · Health Care | SGD 38.2B | SGD 359.4B | SGD 231.76 | 1.41% down | 2% up | ||
| 9 | NovartisNVS · Health Care | SGD 37.1B | SGD 381.8B | SGD 202.15 | 1.50% down | 25% up | ||
| 10 | SanofiSNY · Health Care | SGD 26.8B | SGD 146.9B | SGD 61.16 | 0.23% down | 4% down | ||
| 11 | Novo NordiskNVO · Health Care | SGD 25.1B | SGD 227.1B | SGD 51.54 | 1.82% down | 17% down | ||
| 12 | GSKGSK · Health Care | SGD 24.7B | SGD 126.7B | SGD 63.20 | 0.48% down | 6% up | ||
| 13 | ViatrisVTRS · Health Care | SGD 18.6B | SGD 30.5B | SGD 26.59 | 0.83% up | 96% up | ||
| 14 | Abbott LaboratoriesABT · Health Care | SGD 16.7B | SGD 233.4B | SGD 134.77 | 0.21% down | 17% down | ||
| 15 | ZoetisZTS · Health Care | SGD 11.7B | SGD 44.2B | SGD 108.73 | 0.99% up | 29% down | ||
| 16 | Royalty PharmaRPRX · Health Care | SGD 11.5B | SGD 50.9B | SGD 88.47 | 0.12% down | 78% up | ||
| 17 | Jazz PharmaceuticalsJAZZ · Health Care | SGD 6.9B | SGD 20.2B | SGD 314.71 | 1.38% up | 37% up | ||
| 18 | GenmabGMAB · Health Care | SGD 6.8B | SGD 41.1B | SGD 66.61 | 0.60% down | 70% up | ||
| 19 | Elanco Animal HealthELAN · Health Care | SGD 5.2B | SGD 17.1B | SGD 34.24 | 2.71% up | 20% up | ||
| 20 | Amneal PharmaceuticalsAMRX · Health Care | SGD 3.3B | SGD 9.7B | SGD 27.88 | 2.37% up | 83% up | ||
| 21 | BridgeBio PharmaBBIO · Health Care | SGD 2.6B | SGD 19.6B | SGD 100.39 | 1.35% up | 17% up | ||
| 22 | Regeneron PharmaceuticalsREGN · Health Care | SGD 2.6B | SGD 128.1B | SGD 1,238.21 | 0.24% up | 36% up | ||
| 23 | Ionis PharmaceuticalsIONS · Health Care | SGD 2.3B | SGD 5.8B | SGD 34.81 | 0.11% up | 64% down | ||
| 24 | BeOne MedicinesONC · Health Care | SGD 1.3B | SGD 59.8B | SGD 523.43 | 1.79% down | 17% up | ||
| 25 | Ascendis PharmaASND · Health Care | SGD 1B | SGD 23B | SGD 350.49 | 0.21% up | 28% up | ||
| 26 | InsmedINSM · Health Care | SGD 705.2M | SGD 34.3B | SGD 156.30 | 0.55% down | 40% down | ||
| 27 | Madrigal PharmaceuticalsMDGL · Health Care | SGD 438.3M | SGD 12.6B | SGD 540.32 | 0.72% down | 24% down | ||
| 28 | Legend BiotechLEGN · Health Care | SGD 411.5M | SGD 4.1B | SGD 21.07 | 1.43% up | 42% down | ||
| 29 | CytokineticsCYTK · Health Care | SGD 370.9M | SGD 9.4B | SGD 67.14 | 0.79% up | 20% down | ||
| 30 | TG TherapeuticsTGTX · Health Care | SGD 316.8M | SGD 12.5B | SGD 82.76 | 2.33% up | 107% up | ||
| 31 | Cogent BiosciencesCOGT · Health Care | SGD 287.5M | SGD 6.4B | SGD 37.05 | 3.14% up | 20% down | ||
| 32 | Dr. Reddy's LaboratoriesRDY · Health Care | SGD 249.8M | SGD 16.1B | SGD 19.32 | 1.29% up | 5% up | ||
| 33 | Axsome TherapeuticsAXSM · Health Care | SGD 242.1M | SGD 9.1B | SGD 172.88 | 1.40% down | 7% down | ||
| 34 | Rhythm PharmaceuticalsRYTM · Health Care | SGD 139.5M | SGD 10.6B | SGD 152.18 | 1.19% up | 13% up | ||
| 35 | Definium TherapeuticsDFTX · Health Care | SGD 52.3M | SGD 5.1B | SGD 37.53 | 0.95% down | 169% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total debt is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Total debt is assembled from each company's debt lines and is the least complete of these figures: some companies tag part of their borrowings in ways it misses. Sums are converted from US dollars at today's exchange rate (1 USD = 1.2897 SGD). 26 companies have no total debt on file and are not ranked here.
Questions and answers
Which pharmaceuticals rank first by total debt?
AbbVie (SGD 87B), Pfizer (SGD 83.6B) and Merck & Co (SGD 63.6B) are the top three of the 35 pharmaceuticals ranked by total debt as of 18 Nov 2026, 15:26 UTC.
How many pharmaceuticals are in this ranking?
35 are ranked by total debt. 26 more have no total debt on file and are left out rather than ranked at zero.
What are these pharmaceuticals worth together?
The 35 pharmaceuticals ranked by total debt have a combined market value of SGD 6.58T as of 18 Nov 2026, 15:26 UTC.
What does ranking by total debt measure?
Borrowings at the end of the latest fiscal year: long-term debt including the part due within a year, plus short-term borrowings. Leases are left out unless the company reports them in one figure with its debt.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest pharmaceuticals by total debt”, data as of 18 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=total-debt
Underlying data: Yahoo Finance; SEC EDGAR.